These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 3400078)
1. Correlation of the in vivo anticoagulant, antithrombotic, and antimetastatic efficacy of warfarin in the rat. Smith GF; Neubauer BL; Sundboom JL; Best KL; Goode RL; Tanzer LR; Merriman RL; Frank JD; Herrmann RG Thromb Res; 1988 Apr; 50(1):163-74. PubMed ID: 3400078 [TBL] [Abstract][Full Text] [Related]
2. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats. Morishima Y; Honda Y; Kamisato C; Shibano T Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448 [TBL] [Abstract][Full Text] [Related]
3. Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin? Donati MB; Roncaglioni MC; Falanga A; Casali B; Semeraro N Haemostasis; 1986; 16(3-4):288-94. PubMed ID: 3530903 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of the antimetastatic effect of anticoagulant drugs by immunostimulation in mice. Gorelik E Cancer Res; 1987 Feb; 47(3):809-15. PubMed ID: 3802083 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice. Sato K; Taniuchi Y; Kawasaki T; Hirayama F; Koshio H; Matsumoto Y; Iizumi Y Jpn J Pharmacol; 1998 Oct; 78(2):191-7. PubMed ID: 9829622 [TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Elg M; Gustafsson D; Carlsson S Thromb Res; 1999 May; 94(3):187-97. PubMed ID: 10326765 [TBL] [Abstract][Full Text] [Related]
7. Antitumor and antimetastatic effect of warfarin and heparins. Bobek V; Kovarík J Biomed Pharmacother; 2004 May; 58(4):213-9. PubMed ID: 15183845 [TBL] [Abstract][Full Text] [Related]
8. The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat. MacIomhair M; Lavelle SM Ir J Med Sci; 1996; 165(3):213-8. PubMed ID: 8824029 [TBL] [Abstract][Full Text] [Related]
9. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Colucci M; Delaini F; de Bellis Vitti G; Locati D; Poggi A; Semeraro N; Donati MB Biochem Pharmacol; 1983 Jun; 32(11):1689-91. PubMed ID: 6870908 [TBL] [Abstract][Full Text] [Related]
11. The disposition of the enantiomers of warfarin following chronic administration to rats: relationship to anticoagulant response. Pratt SK; Winn MJ; Park BK J Pharm Pharmacol; 1989 Nov; 41(11):743-6. PubMed ID: 2576040 [TBL] [Abstract][Full Text] [Related]
12. T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats. Ohtani A; Murakami J; Hirano-Wakimoto A Eur J Pharmacol; 1997 Jul; 330(2-3):151-6. PubMed ID: 9253948 [TBL] [Abstract][Full Text] [Related]
13. Cancer cell procoagulants and their pharmacological modulation. Donati MB; Semeraro N Haemostasis; 1984; 14(5):422-9. PubMed ID: 6398243 [TBL] [Abstract][Full Text] [Related]
14. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Sato K; Kaku S; Hirayama F; Koshio H; Matsumoto Y; Kawasaki T; Iizumi Y Eur J Pharmacol; 1998 Jul; 352(1):59-63. PubMed ID: 9718268 [TBL] [Abstract][Full Text] [Related]
15. The relationship between the vitamin K cycle inhibition and the plasma anticoagulant response at steady-state S-warfarin conditions in the rat. Mosterd JJ; Thijssen HH J Pharmacol Exp Ther; 1992 Mar; 260(3):1081-5. PubMed ID: 1545379 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792 [TBL] [Abstract][Full Text] [Related]
17. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432 [TBL] [Abstract][Full Text] [Related]
18. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155 [TBL] [Abstract][Full Text] [Related]
19. Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? Zeuthen EL; Lassen JF; Husted SE Thromb Res; 2003 Mar; 109(5-6):241-6. PubMed ID: 12818245 [TBL] [Abstract][Full Text] [Related]
20. Experimental arterial thrombosis in genetically or diet induced hyperlipidemia in rats--role of vitamin K-dependent clotting factors and prevention by low-intensity oral anticoagulation. De Curtis A; D'Adamo MC; Amore C; Polishchuck R; Castelnuovo AD; Donati MB; Iacoviello L Thromb Haemost; 2001 Dec; 86(6):1440-8. PubMed ID: 11776312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]